NCT04828460

Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 3,500 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general population and good short-term tolerance. The efficacy of these vaccines ranges from 62 to 95%, which is particularly remarkable, especially for mRNA vaccines. Nevertheless, these studies do not report the vaccine response in organ transplant patients. It is known that transplant patients have lower vaccine responses than immunocompetent patients due to some degree of immunosuppression. Therefore, the investigators are interested in evaluating the vaccine response of organ transplant recipients after vaccination against SARS- CoV-2. For non-responder patients, new strategies can be proposed: 3rd or 4th boost of vaccine or perfusion/injection of antiS monoclonal antibodies. These strategies must be evaluated.

Conditions

• Covid19
• Kidney Transplantation

Timeline

• Start date: 2021-02-09
• Primary completion: 2021-12-01
• Completion: 2023-02-01
• First posted: 2021-04-02
• Last updated: 2021-11-09

Locations

1 site across 1 country: France